Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer - Scorecard - MDSpire

Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer

  • By

  • Cody Z. Watling

  • Longgang Zhao

  • Xinyuan Zhang

  • Emily Deubler

  • Amparo G. Gonzalez-Feliciano

  • Barry I. Graubard

  • Jessica L. Petrick

  • Aika Wojt

  • Gisela Butera

  • Jonathan N. Hofmann

  • Laura E. Beane Freeman

  • Martha J. Shrubsole

  • Wei Zheng

  • Staci L. Sudenga

  • Eva Schernhammer

  • A. Heather Eliassen

  • Lorelei A. Mucci

  • Howard D. Sesso

  • Rashmi Sinha

  • Erikka Loftfield

  • Caroline Y. Um

  • Marjorie L. McCullough

  • Mazda Jenab

  • Xuehong Zhang

  • Katherine A. McGlynn

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Consumption of Artificial and Sugar-Sweetened Beverages and Its Association with Liver Cancer Risk

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationIndividuals consuming ASB and SSB, particularly those with diabetes and metabolic disorders.
Care Setting

Key Highlights

  • Add a highlight: 'Current evidence shows inconsistent associations between ASB and SSB intake and liver cancer risk.'

Guideline-Based Recommendations

Diagnosis

    Management

    • No specific management recommendations provided in the source material; clarify this in the text.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify that no specific treatment insights are provided in the source material.

        Clinical Best Practices

        • Add: 'Regularly assess liver function in individuals with high ASB and SSB intake.'

        Related Resources & Content

        Original Source(s)

        Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer

        • by Cody Z. Watling, Longgang Zhao, Xinyuan Zhang, Emily Deubler, Amparo G. Gonzalez-Feliciano, Barry I. Graubard, Jessica L. Petrick, Aika Wojt, Gisela Butera, Jonathan N. Hofmann, Laura E. Beane Freeman, Martha J. Shrubsole, Wei Zheng, Staci L. Sudenga, Eva Schernhammer, A. Heather Eliassen, Lorelei A. Mucci, Howard D. Sesso, Rashmi Sinha, Erikka Loftfield, Caroline Y. Um, Marjorie L. McCullough, Mazda Jenab, Xuehong Zhang, Katherine A. McGlynn

        • June 10, 2026

        Related Content

        Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

        Comparison of surgical outcomes of robotic complete mesocolic excision for right-sided colon cancer in obese versus non-obese patients

        Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study